Harvard’s Verdine Aims To Retire Become Full-Time FogPharma CEO

February 23, 2017 | Harvard University chemical biologist Greg Verdine is planning to retire, aiming to maintain a "ferocious independence" as a full-time biotech CEO. Xconomy